AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19070356
Drug: Combination inhaled
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaled corticosteroid with a long-acting beta-agonist
Trial: 17187165
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg nightly for one year
Trial: 17187165
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 or 100 mg as needed for 12 months
Trial: 9771058
Drug: Reflexology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatment (14 sessions over four months)
Trial: 2655436
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg
Trial: 2655436
Drug: Lactulose 30
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 30 g
Trial: 369673
Drug: Self-recording and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-recording and monthly home visits
Trial: 369673
Drug: Monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly home visits only
Trial: 369673
Drug: Neither self-recording
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither self-recording nor monthly home visits
Trial: 28399611
Drug: Blue-water infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-water infusion colonoscopy (BWIC)
Trial: 21177516
Drug: Self-Administered Computer-Aided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Administered Computer-Aided Exposure (CAE-SA)
Trial: 19761717
Drug: Dihydroartemisinin (DHA)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artenimol (DB11638)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Dihydroartemisinin (DHA) 300 mg daily for 2 days
Trial: 19761717
Drug: Artesunate 300
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate 300 mg daily for 2 days
Trial: 17514186
Drug: Donepezil (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (titrated to 10 mg daily)
Trial: 15496603
Drug: Cow milk
RxNorm normalized name: cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow milk formula with 72 mg/L supplemental ribonucleotides (FN)
Trial: 11464223
Drug: Mayonnaise containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mayonnaise containing phytosterols (PS) dissolved in diacylglycerol (DG) (500 mg/day PS, 10 g/day DG)
Trial: 11464223
Drug: Mayonnaise containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mayonnaise containing phytosterols (PS) dispersed in triacylglycerol (TG) (500 mg/day PS, 10 g/day TG)
Trial: 7602354
Drug: Edatrexate (EDX)
RxNorm normalized name: EDX-502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edatrexate (EDX) at an initial dose of 80 mg/m2/wk (later reduced to 70 mg/m2/wk)
Trial: 7602354
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) at a dose of 40 mg/m2/wk
Trial: 20641058
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng extract (3 g/day)
Trial: 15061827
Drug: Rivastigmine treatment
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine treatment for 12 months
Trial: 11258692
Drug: Inhaled anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anti-inflammatory medication (inhaled steroids)
Trial: 11770189
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg per day for 6 months)
Trial: 11770189
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (ccHRT: 2 mg estradiol and 1 mg norethisterone acetate per day for 6 months)
Trial: 3468226
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate 100 mg + Acetaminophen 650 mg
Trial: 2199415
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic prophylaxis for contaminated head and neck cases and endonasal sinus surgery
Trial: 2199415
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis for most clean cases
Trial: 31902533
Drug: Computer-aided design
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-aided design and computer-aided manufacturing (CAD-CAM) lithium disilicate crowns (CC)
Trial: 31902533
Drug: Biological complications
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological complications for crowns
Trial: 31902533
Drug: Biological complications
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological complications for FPDs
Trial: 31064365
Drug: COSMOS intervention
RxNorm normalized name: Cosmos sulphureus flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COSMOS intervention (educational programs, training in clinical evaluation, interprofessional medication review with collegial mentoring)
Trial: 28914503
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (testosterone replacement therapy, n = 20)
Trial: 17515584
Drug: Unblinding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unblinding of treatment name
Trial: 7651068
Drug: Gentamicin 4
RxNorm normalized name: gentamicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4 mg/kg by infusion over 30 minutes once daily (Single-Dose Group, SG) (N = 25)
Trial: 7651068
Drug: Gentamicin 2
RxNorm normalized name: gentamicin 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 2 mg/kg intravenously twice daily (Double-Dose Group, DG) (N = 29)
Trial: 16791
Drug: Ketazolam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketazolam (15 mg capsules, flexible dosage range of 15-75 mg, average optimum therapeutic dose of 46.9 mg once daily at bedtime)
Trial: 26590478
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS (1-Hz) combined with NRT (21-mg patch) for 2 weeks
Trial: 26590478
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS combined with NRT (21-mg patch) for 2 weeks
Trial: 20642485
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (4 to 7 mL of oxygen ozone mixture)
Trial: 20642485
Drug: Ozone-PIRFT (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone-PIRFT (combined oxygen-ozone therapy with radiofrequency lesioning at 80°C for 360 s)
Trial: 17893293
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen 0.625 mg/medroxyprogesterone acetate 2.5 mg for 4 months
Trial: 9877000
Drug: Repaglinide 2
RxNorm normalized name: repaglinide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2 mg as tablet
Trial: 9877000
Drug: Repaglinide 2
RxNorm normalized name: repaglinide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2 mg as oral solution
Trial: 9877000
Drug: Repaglinide 2
RxNorm normalized name: repaglinide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2 mg as intravenous infusion
Trial: 7975854
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (rapid schedule: vaccination at 0, 1, 2 and 12 months)
Trial: 7975854
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (standard schedule: vaccination at 0, 1, and 6 months)
Trial: 7975854
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (rapid schedule)
Trial: 7975854
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (standard schedule)
Trial: 27547757
Drug: Desflurane anaesthesia
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane anaesthesia (1 MAC) + propofol infusion (2-3 mg/kg/h)
Trial: 27547757
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (5-6 mg/kg/h)
Trial: 25112085
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg, three times per day)
Trial: 17505263
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily) and coenzyme Q10 (400 mg/day)
Trial: 17505263
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily)
Trial: 9836549
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 or 10 g daily for 5 weeks)
Trial: 31111580
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy without bismuth (esomeprazole 40 mg twice a day plus amoxicillin 1 g three times a day)
Trial: 24621858
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Trial: 24621858
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Trial: 24621858
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) administration of DNA vaccine (0.4 mg) and rAd5 (1010 PU)
Trial: 23363065
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg twice a day for 4 weeks
Trial: 21039220
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25)
Trial: 21039220
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26)
Trial: 21039220
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (high-dose and standard-dose)
Trial: 19043154
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list followed by 15 sessions of therapist cognitive-behavioural therapy (CBT)
Trial: 15963389
Drug: Bivalirudin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin with provisional GP IIb/IIIa inhibitors
Trial: 10789668
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg/d for up to 21 days
Trial: 8842277
Drug: Cefonicid prophylaxis
RxNorm normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefonicid prophylaxis (1 g intravenously) 1 hour before the procedure
Trial: 23161038
Drug: L-arginine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (2 g tid or 4 g tid)
Trial: 20123315
Drug: Rolofylline 30
RxNorm normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolofylline 30 mg intravenously daily for 3 days
Trial: 18308809
Drug: High-dose ATD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATD
Trial: 18308809
Drug: Low-dose ATD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATD
Trial: 12036724
Drug: HPMC capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC capsules (oral administration)
Trial: 12036724
Drug: HPMC capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC capsules (rectal administration)
Trial: 12036724
Drug: Gelatine capsules
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine capsules (oral administration)
Trial: 12036724
Drug: Gelatine capsules
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine capsules (rectal administration)
Trial: 12036724
Drug: HPMC capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC capsules (various viscosity grades)
Trial: 10520777
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (lepirudin, i.v. bolus of 0.2 mg/kg, followed by s.c. injections of 0.5 mg/kg b.i.d. for 5 to 7 days)
Trial: 10520777
Drug: Heparin (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (i.v. placebo bolus, followed by s.c. injections of 12,500 IU b.i.d. for 5 to 7 days)
Trial: 7872337
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg immediately and twice daily thereafter (outpatient management)
Trial: 7872337
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg immediately and twice daily thereafter (inpatient management)
Trial: 2779095
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice a day
Trial: 2779095
Drug: Gemfibrozil plus
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil plus colestipol 10 grams twice a day
Trial: 31570942
Drug: Diversion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diversion group (blood drawn into lithium heparin tube before blood culture bottles)
Trial: 31570942
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (blood cultures first, then lithium heparin tube)
Trial: 27883209
Drug: Tongue-to-palate resistance
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue-to-palate resistance training (TPRT) for 4 weeks (5 days per week) plus traditional dysphagia therapy
Trial: 27883209
Drug: TPRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPRT plus traditional dysphagia therapy
Trial: 21969643
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release plus escitalopram
Trial: 21969643
Drug: Venlafaxine extended-release
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended-release plus mirtazapine
Trial: 21800009
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin BID
Trial: 21800009
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg aspirin OD
Trial: 19380597
Drug: Pagibaximab (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab (10, 30, 60, or 90 mg/kg of body weight)
Trial: 16271272
Drug: Regimen I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I: oral praziquantel (40 mg/kg body weight)
Trial: 16271272
Drug: Regimen II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II: oral ivermectin (200 microg/kg body weight) with oral albendazole (400 mg)
Trial: 16271272
Drug: Regimen III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen III: oral ivermectin with oral albendazole and praziquantel
Trial: 16271272
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of all three drugs (albendazole, praziquantel, ivermectin)
Trial: 9052592
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to established protocol (physician‐chosen combinations of intracervical or vaginal prostaglandins every 4‐6 hours, artificial rupture of membranes, and oxytocin infusion)
Trial: 8498881
Drug: Alprazolam 0.25
RxNorm normalized name: alprazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.25 mg three times daily from menstrual cycle day 16
Trial: 8498881
Drug: Alprazolam 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.50 mg three times daily
Trial: 8498881
Drug: Alprazolam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.75 mg three times daily from menstrual cycle day 16
Trial: 30255720
Drug: Intravenous delta-9-tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous delta-9-tetrahydrocannabinol (0.015 mg/kg)
Trial: 30255720
Drug: Intravenous delta-9-tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous delta-9-tetrahydrocannabinol (0.03 mg/kg)
Trial: 21492884
Drug: Cinacalcet 60
RxNorm normalized name: cinacalcet 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 60 mg single dose
Trial: 21036880
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg bid) combined with TACE (doxorubicin 50 mg)
Trial: 21036880
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg bid)
Trial: 18408077
Drug: Renilon 7.5(R)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renilon 7.5(R) oral supplement, 2 packs of 125-ml daily for 3 months
Trial: 15936131
Drug: Swanson metacarpophalangeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swanson metacarpophalangeal implants
Trial: 15936131
Drug: Sutter metacarpophalangeal
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutter metacarpophalangeal implants
Trial: 1803828
Drug: Danazol 600
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600 mg/daily for 3 months plus local immunosuppressive treatment combined with superovulation and IPI
Trial: 6819028
Drug: Vitamin-only supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-only supplementation (vitamin C 30 mg daily, iron 3 mg daily)
Trial: 25461789
Drug: Computer-Based Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Based Training for Cognitive Behavioral Therapy (CBT4CBT)
Trial: 9930401
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (0.8 g x 3 capsules/d)
Trial: 9930401
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil with vitamin E (FOE) supplementation (0.8 g x 3 capsules/d with 3 IU/g vitamin E)
Trial: 31948337
Drug: Breakfast meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast meal with 9 g fat and 25 g sugar
Trial: 31948337
Drug: Breakfast meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast meal with 28 g fat and 18 g sugar
Trial: 31948337
Drug: Breakfast meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast meal with 5 g fat and 56 g sugar
Trial: 28893130
Drug: Bite&White treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bite&White treatment
Trial: 26541501
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy delivered in Spanish (MET‐S)
Trial: 26541501
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy delivered in English (MET‐E)
Trial: 18300985
Drug: Ketorolac and
RxNorm normalized name: Ketorolac and phenylephrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac and bupivacaine (30 mg and 150 mg, respectively)
Trial: 17030772
Drug: Self-administered ALSFRS-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered ALSFRS-R
Trial: 17030772
Drug: Standard evaluator-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard evaluator-administered ALSFRS-R